Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Biochemical and Biophysical Research Communications - BBRC

• Publication date

  2004-08-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.BBRC.2004.06.153PMID 15358192
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative analysis of adenoviral transgene delivery via tail or portal vein into rat liver

  2004cited by this paper
• Inhibitory effect of soluble PDGF-beta receptor in culture-activated hepatic stellate cells.

  2004cited by this paper
• CSRP2, TIMP‐1, and SM22α promoter fragments direct hepatic stellate cell‐specific transgene expression in vitro, but not in vivo

  2004cited by this paper
• Dominant-negative soluble PDGF-β receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis

  2004cited by this paper
• The Role of Focal Adhesion Kinase-Phosphatidylinositol 3-Kinase-Akt Signaling in Hepatic Stellate Cell Proliferation and Type I Collagen Expression*

  2003cited by this paper
• Adenoviral-mediated transfer of p53 or retinoblastoma protein blocks cell proliferation and induces apoptosis in culture-activated hepatic stellate cells.

  2003cited by this paper
• The Myofibroblastic Conversion of Peribiliary Fibrogenic Cells Distinct from Hepatic Stellate Cells Is Stimulated by Platelet-Derived Growth Factor During Liver Fibrogenesis

  2003cited by this paper
• Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents

  2003cited by this paper
• Variables Affecting In Vivo Performance of High-Capacity Adenovirus Vectors

  2002cited by this paper
• Ancient Pathways Programmed by Small RNAs

  2002cited by this paper
• Adenoviral delivery of an antisense RNA complementary to the 3' coding sequence of transforming growth factor-beta1 inhibits fibrogenic activities of hepatic stellate cells.

  2002cited by this paper
• Chronic myelogenous leukemia.

  2002cited by this paper
• Role for a bidentate ribonuclease in the initiation step of RNA interference

  2001cited by this paper
• Chronic myelogenous leukemia

  2001cited by this paper
• LIM-domain protein cysteine- and glycine-rich protein 2 (CRP2) is a novel marker of hepatic stellate cells and binding partner of the protein inhibitor of activated STAT1.

  2001cited by this paper
• TNFalpha and IFNgamma induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression.

  2001cited by this paper
• Hepatic Stellate Cell Proliferation is an Early Platelet-Derived Growth Factor-Mediated Cellular Event in Rat Cholestatic Liver Injury

  2001cited by this paper
• TNFα and IFNγ Induced by Innate Anti-adenoviral Immune Responses Inhibit Adenovirus-Mediated Transgene Expression

  2001cited by this paper
• Imaging of Dynamic Changes of the Actin Cytoskeleton in Microextensions of Live NIH3T3 Cells with a GFP Fusion of the F-Actin Binding Domain of Moesin

  2000cited by this paper
• Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury*

  2000cited by this paper
• RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals.

  2000cited by this paper
• Comparative evaluation of gene delivery devices in primary cultures of rat hepatic stellate cells and rat myofibroblasts

  2000cited by this paper
• PDGF-Mediated Chemoattraction of Hepatic Stellate Cells by Bile Duct Segments in Cholestatic Liver Injury

  2000cited by this paper
• Variation in the reversibility of evolution

  2000cited by this paper
• Cellular Immunity Delimits Adenoviral Gene Therapy Strategies for the Treatment of Neoplastic Diseases

  1999cited by this paper
• Molecular mechanisms of action of antisense drugs.

  1999cited by this paper
• Extracellular signal‐regulated kinase activation differentially regulates platelet‐derived growth factor's actions in hepatic stellate cells, and is induced by In Vivo liver injury in the rat

  1999cited by this paper
• Expression of platelet-derived growth factor in newly formed cholangiocytes during experimental biliary fibrosis in rats.

  1999cited by this paper
• AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation.

  1999cited by this paper
• Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

  1998cited by this paper
• Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's actions on hepatic stellate cells.

  1997cited by this paper
• 2′-O-(2-Methoxy)ethyl-modified Anti-intercellular Adhesion Molecule 1 (ICAM-1) Oligonucleotides Selectively Increase the ICAM-1 mRNA Level and Inhibit Formation of the ICAM-1 Translation Initiation Complex in Human Umbilical Vein Endothelial Cells*

  1997cited by this paper
• Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis.

  1996cited by this paper
• Cytokines and cellular crosstalk involved in the activation of fat-storing cells.

  1995cited by this paper
• Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo.

  1995cited by this paper
• Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo.

  1995cited by this paper
• Growth factor and procollagen type I gene expression in human liver disease.

  1995cited by this paper
• Cytokines and cellular crosstalk involved in the activation of fat-storing cells.

  1995cited by this paper
• Platelet-derived growth factor receptor signals.

  1994cited by this paper
• Expression of platelet‐derived growth factor in a model of acute liver injury

  1994cited by this paper
• Regulation of platelet-derived growth factor secretion and gene expression in human liver fat-storing cells.

  1994cited by this paper
• Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture.

  1994cited by this paper
• The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies

  1993cited by this paper
• Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies.

  1993cited by this paper
• Induction of platelet-derived growth factor alpha- and beta-receptor mRNA and protein by platelet-derived growth factor BB.

  1991cited by this paper
• Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors.

  1989cited by this paper
• Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells.

  1989cited by this paper
• Proliferation of fat-storing cells is stimulated by secretions of Kupffer cells from normal and injured liver.

  1988cited by this paper
• A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5.

  1988cited by this paper
• A significant part of macrophage-derived growth factor consists of at least two forms of PDGF.

  1985cited by this paper
• A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections.

  1985cited by this paper
• Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat.

  1984cited by this paper
• Alterations to controls of cellular DNA synthesis by adenovirus infection

  1981cited by this paper
• Preparation of isolated rat liver cells.

  1976cited by this paper

• A Guide to Pathophysiology, Signaling Pathways, and Preclinical Models of Liver Fibrosis.

  2025cites this paper
• Hydroxyurea attenuates hepatic stellate cell proliferation in vitro and liver fibrogenesis in vivo

  2023cites this paper
• Extracellular Matrix Remodeling in Chronic Liver Disease

  2021cites this paper
• Progress in research on the roles of TGR5 receptor in liver diseases

  2021cites this paper
• Reversine and herbal Xiang–Sha–Liu–Jun–Zi decoction ameliorate thioacetamide-induced hepatic injury by regulating the RelA/NF-κB/caspase signaling pathway

  2020cites this paper
• Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease

  2020cites this paper
• Key Players of Hepatic Fibrosis

  2020cites this paper
• ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis

  2019cites this paper
• Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice

  2018cites this paper
• The multifaceted roles of perlecan in fibrosis.

  2018cites this paper
• Amendment history : Corrigendum ( April 2005 ) Liver fibrosis Ramón Bataller

  2018cites this paper
• A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis

  2018cites this paper
• Relationship between Liver Pathology and Disease Progression in a Murine Model of Amyotrophic Lateral Sclerosis

  2018cites this paper
• The PDGF/PDGFR pathway as a drug target.

  2017cites this paper
• The good and the bad collagens of fibrosis – Their role in signaling and organ function

  2017cites this paper
• The common dietary flavonoid myricetin attenuates liver fibrosis in carbon tetrachloride treated mice

  2017cites this paper
• Therapeutic pro-fibrogenic signaling pathways in fibroblasts.

  2017influential citation
• Current Understanding of Stem Cell and Secretome Therapies in Liver Diseases

  2017cites this paper
• Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model

  2017cites this paper
• Hepatic Retinyl Ester Hydrolases and the Mobilization of Retinyl Ester Stores

  2016cites this paper
• Obesity: An Immunometabolic Perspective

  2016cites this paper
• Protein degradation fragments as diagnostic and prognostic biomarkers of connective tissue diseases: understanding the extracellular matrix message and implication for current and future serological biomarkers

  2016cites this paper
• The PDGF system and its antagonists in liver fibrosis.

  2016cites this paper
• Targeted Therapies in Liver Fibrosis: Combining the Best Parts of Platelet-Derived Growth Factor BB and Interferon Gamma

  2015cites this paper
• Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.

  2015cites this paper
• Actions of Huangqi decoction against rat liver fibrosis: a gene expression profiling analysis

  2015cites this paper
• Platelet-Derived Growth Factor and Transforming Growth Factor β1 Regulate ARDS-Associated Lung Fibrosis Through Distinct Signaling Pathways

  2015cites this paper
• Characterization of binding mode of action of a blocking anti-platelet-derived growth factor (PDGF)-B monoclonal antibody, MOR8457, reveals conformational flexibility and avidity needed for PDGF-BB to bind PDGF receptor-β.

  2015cites this paper
• ACCURACY OF LIVER STIFFNESS MEASUREMENT USING FIBROSCAN ® TO PREDICT THE RESPONSE TO ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C VIRAL INFECTION

  2015cites this paper
• Macrophage migration inhibitory factor is required for recruitment of scar‐associated macrophages during liver fibrosis

  2015cites this paper
• Fluorofenidone attenuates hepatic fibrosis by suppressing the proliferation and activation of hepatic stellate cells.

  2014cites this paper
• Factor VII activating protease (FSAP): A novel protective factor in liver fibrosis

  2014cites this paper
• Pathogenesis of liver cirrhosis.

  2014cites this paper
• The Role of Extracellular Matrix Quality in Pulmonary Fibrosis

  2014cites this paper
• Virus-related liver cirrhosis: molecular basis and therapeutic options.

  2014cites this paper
• Adipose Tissue-derived Mesenchymal Stem Cells in Regenerative Medicine Treatment for Liver Cirrhosis - Focused on Efficacy and Safety in Preclinical and Clinical

  2014influential citation
• Scientifico disciplinare : MED 09 ACCURACY OF LIVER STIFFNESS MEASUREMENT USING FIBROSCAN ® TO PREDICT THE RESPONSE TO ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C VIRAL INFECTION

  2014cites this paper
• A new histone deacetylase inhibitor improves liverfibrosis in BDL rats through suppression of hepatic stellate cells

  2014cites this paper
• The antihepatic fibrotic effects of fluorofenidone via MAPK signalling pathways

  2013cites this paper
• Cellular basis of hepatic fibrosis and its role in inflammation and cancer.

  2013cites this paper
• Chapter 6 – Liver fibrogenesis: Mechanisms and clinical relevance

  2012cites this paper
• MOLLECULAR HEPATIC STELLATE CELLS TARGETS IN ANTIFIBROTIC THERAPY

  2012cites this paper
• Understanding the Mechanism of Hepatic Fibrosis and Potential Therapeutic Approaches

  2012cites this paper
• Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease

  2012cites this paper
• A role for autophagy during hepatic stellate cell activation.

  2012cites this paper
• Vaccination with Platelet-Derived Growth Factor B Kinoids Inhibits CCl4-Induced Hepatic Fibrosis in Mice

  2012influential citation
• Oral application of 1,7‐dimethylxanthine (paraxanthine) attenuates the formation of experimental cholestatic liver fibrosis

  2011cites this paper
• Gene transcriptional networks integrate microenvironmental signals in human breast cancer.

  2011cites this paper
• Mechanisms of hepatic fibrogenesis.

  2011cites this paper
• Fibrosis as a Major Mechanism of Chronic Liver Disease

  2011cites this paper
• New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis.

  2010cites this paper
• The development of a novel in vitro model of human liver for the study of disease pathogenesis

  2010cites this paper
• Investigación de nuevas estrategias terapeúticas para la inflamación y la fibrosis hepática.

  2010cites this paper
• Anti‐PDGF‐B monoclonal antibody reduces liver fibrosis development

  2010cites this paper
• Therapeutic efficacy of Traditional Chinese Medicine 319 recipe on hepatic fibrosis induced by carbon tetrachloride in rats.

  2009cites this paper
• Altered factor VII activating protease expression in murine hepatic fibrosis and its influence on hepatic stellate cells

  2009cites this paper
• State-of-the-Art Lecture: Mechanisms of liver fibrosis — targets for therapy

  2009cites this paper
• Hepatic injury in metabolic syndrome: the role of selenium in models of hepatic injury and healing

  2009cites this paper
• The Marburg I variant (G534E) of the factor VII–activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet‐derived growth factor BB

  2009cites this paper
• The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis.

  2009cites this paper
• Targeted inhibition of platelet-derived growth factor receptor-β subunit in hepatic stellate cells ameliorates hepatic fibrosis in rats

  2008cites this paper
• Cytokines in Liver Diseases

  2008cites this paper
• Advances in antifibrotic therapy

  2008cites this paper
• Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies

  2008cites this paper
• Prevention of CCl4-induced liver cirrhosis by ribbon antisense to transforming growth factor-beta1.

  2008cites this paper
• RNA interference targeting the platelet-derived growth factor receptor β subunit ameliorates experimental hepatic fibrosis in rats

  2008cites this paper
• A gain-of-function mutation in the PDGFR-β alters the kinetics of injury response in liver and skin

  2008cites this paper
• Hepatic fibrosis -- overview.

  2008cites this paper
• Mechanisms of hepatic fibrogenesis.

  2008cites this paper
• Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury

  2008cites this paper
• Cytokines and renin-angiotensin system signaling in hepatic fibrosis.

  2008cites this paper
• Pro-fibrogenic potential of PDGF-D in liver fibrosis.

  2007cites this paper
• Inhibitory effects of prostaglandin E1 on activation of hepatic stellate cells in rabbits with schistosomiasis.

  2007cites this paper
• [Therapeutical targets for revert liver fibrosis].

  2007cites this paper
• Blancos terapéuticos potenciales para revertir la cirrosis hepática

  2007cites this paper
• Role of hepatic stellate cells and correlated cytokines in the formation of hepatic fibrosis

  2007cites this paper
• PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis.

  2007cites this paper
• Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosis.

  2007cites this paper
• Prevention of CCl 4-induced liver cirrhosis by ribbon antisense to transforming growth factor-ß 1

  2007cites this paper
• Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ.

  2007cites this paper
• Gene modulation for treating liver fibrosis.

  2007cites this paper
• Mouse Models of Liver Fibrosis

  2007cites this paper
• [Pathogenesis of liver fibrosis].

  2007cites this paper
• Molecular therapy for hepatic injury and fibrosis: where are we?

  2006cites this paper
• Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats.

  2006cites this paper
• Addressing liver fibrosis with lipid-based drug carriers targeted to hepatic stellate cells

  2006cites this paper
• Phospholipase D and extracellular signal-regulated kinase in hepatic stellate cells: effects of platelet-derived growth factor and extracellular nucleotides.

  2006cites this paper
• Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice.

  2006cites this paper
• PI3K is involved in PDGF-beta receptor upregulation post-PDGF-BB treatment in mouse HSC.

  2006cites this paper
• Angiotensin Converting Enzyme in the Pathophysiology of Liver Fibrosis

  2006cites this paper
• Genetic and nongenetic factors associated with fibrosis progression in different types of chronic liver diseases

  2005cites this paper
• Fibrosis in chronic liver diseases: diagnosis and management.

  2005cites this paper
• Liver fibrosis.

  2005cites this paper
• liver fibrosis with lipid-based drug carriers targeted to hepatic stellate cells

  year unknowncites this paper